Immutep Limited (IMMP): Firm Reports Positive Data from Trials

Immutep Limited (NASDAQ:IMMP) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.

Immutep Limited (IMMP): Firm Reports Positive Data from Trials

In mid-November, Immutep Limited (NASDAQ:IMMP) reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. The firm revealed that a Phase 2 study of efti in combination with radiotherapy and Merck’s Keytruda showed significant efficacy in treating patients with soft tissue sarcoma in the neoadjuvant setting. The biotech company also reported a 24-month overall survival rate of 81% from a Phase 1 study of efti in combination with Keytruda and chemotherapy as a first-line treatment for metastatic non-squamous non-small cell lung cancer.

The firm recently announced that a Phase III trial for a drug as first-line treatment for advanced or metastatic non-small cell lung cancer had enrolled and randomised over 170 patients, reaching an important milestone, as this is above the amount necessary to conduct the futility analysis. Marc Voigt, the CEO of Immutep Limited (NASDAQ:IMMP), has said that his firm is pleased with the pace of enrolment in the trial and believes it has the potential to change the treatment landscape in non-small cell lung cancer.

Immutep Limited (NASDAQ:IMMP) is a biotechnology company that engages in developing novel Lymphocyte Activation Gene-3-related immunotherapies for cancer and autoimmune diseases in Australia.

While we acknowledge the potential of IMMP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IMMP and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term

Disclosure. None.